Hepatic Inflammatory and Fibrotic Microenvironment (null)

The **hepatic inflammatory and fibrotic microenvironment** refers to the complex interplay between immune cells (such as Kupffer cells, macrophages, neutrophils, T cells), non-immune stromal cells (e.g., hepatic stellate cells, fibroblasts, endothelial cells), and signaling molecules (e.g., cytokines, chemokines, growth factors) within the liver during chronic injury, infection, or metabolic insult. Persistent inflammation, initiated by damage-associated (DAMPs) and pathogen-associated molecular patterns (PAMPs), leads to the recruitment and activation of immune cells, excessive release of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6), and chronic activation of hepatic stellate cells, resulting in fibrotic tissue remodeling and cirrhosis[1][2][3]. These microenvironmental changes are central to the progression of liver diseases including viral hepatitis, alcoholic/non-alcoholic steatohepatitis, advanced fibrosis, and hepatocellular carcinoma[4][5]. Therapies often aim to target components within this environment (such as specific cytokines or signaling pathways like STAT3 or TGF-β), rather than the microenvironment as a singular, canonical molecular target. **Summary:** "Hepatic Inflammatory and Fibrotic Microenvironment" is a pathophysiological context and not a discrete drug target; it encompasses multiple cellular and molecular interactions driving liver disease progression[1][2][3][4][5].

Other names

Hepatic microenvironmentLiver tumor microenvironmentLiver fibroinflammatory microenvironmentFibrotic liver microenvironment

Immunomodulation (targeting inflammatory cytokines); Inhibition of fibrogenesis pathways (e.g., TGF-β signaling, STAT3 pathway); Modulation of cell-cell and cell-ECM interactions; Targeting myofibroblast activation and recruitment; Null for single-molecule mechanism